Want to see CH:SDZ full AI Analyst Report?
Top Page
Sandoz Group Ltd
(SDZ)
Select Model
Select Model
Rating:62Neutral
Price Target:
CHF72.00
▲(13.17% Upside)
Action:Reiterated
Date:08/06/26
The score is primarily supported by improved financial performance in 2025 (profitability rebound and stronger cash generation) and a generally positive price trend versus long-term moving averages. Offsetting factors are a demanding valuation (high P/E with modest yield) and mixed near-term technical momentum (negative MACD).
Positive Factors
Revenue & profit rebound
A ~25% revenue increase and net margin recovery to ~8% in 2025 reflects a meaningful operational turnaround versus prior years. This durable improvement indicates restored pricing, volume or product mix dynamics and supports sustained cash generation and return-on-equity if management maintains execution.
Negative Factors
Earnings & FCF volatility
Wide swings in free cash flow across years indicate sensitivity to working capital, product timing and investment cycles. Such volatility complicates capital allocation, makes forecasting harder, and raises execution risk for sustaining investments in manufacturing, R&D or commercial launch programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & profit rebound
A ~25% revenue increase and net margin recovery to ~8% in 2025 reflects a meaningful operational turnaround versus prior years. This durable improvement indicates restored pricing, volume or product mix dynamics and supports sustained cash generation and return-on-equity if management maintains execution.
Read all positive factors
Sandoz Group Ltd (SDZ) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF28.93B
Dividend Yield1.22%
Average Volume (3M)677.45K
Price to Earnings (P/E)38.2
Beta (1Y)0.81
Revenue Growth0.80%
EPS Growth28043.55%
CountryCH
Employees22,356
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.13
Shares Outstanding440,000,000
10 Day Avg. Volume616,025
30 Day Avg. Volume677,447
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.35
Price to Sales (P/S)2.82
P/FCF Ratio38.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF77.20Price Target Upside21.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)4.08
Revenue Forecast (FY)CHF12.11B
Sandoz Group Ltd Business Overview & Revenue Model
Company Description
Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pha...
How the Company Makes Money
Sandoz primarily makes money by selling off-patent medicines—generics and biosimilars—through business-to-business channels to wholesalers, pharmacies, hospitals, and healthcare systems, as well as through tenders and contracted supply arrangement...
Sandoz Group Ltd Earnings Call Summary
Earnings Call Date:Mar 13, 2024
(Q4-2023)
| % Change Since: |
Next Earnings Date:Mar 17, 2027
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with strong sales growth, particularly in the biosimilars segment and North American market recovery. However, the financial performance was impacted by negative free cash flow, a decline in core EBITDA margin, significant restructuring, and legal costs.Positive Updates
Strong Sales Growth
Fourth quarter 2023 was the strongest consecutive quarter of top line growth, with sales up 10% compared to the previous year. For the full year, sales grew 7% to $9.6 billion, with volume contributing 10 percentage points of growth.
Negative Updates
Negative Free Cash Flow
The free cash flow was negative $234 million for 2023, attributed to significant investments needed for the transition to a standalone company and other strategic initiatives.
Read all updates
Q4-2023 Updates
Positive
Negative
Strong Sales Growth
Fourth quarter 2023 was the strongest consecutive quarter of top line growth, with sales up 10% compared to the previous year. For the full year, sales grew 7% to $9.6 billion, with volume contributing 10 percentage points of growth.
Read all positive updates
Company Guidance
During the Sandoz Q4 2023 earnings call, the company reported a strong financial performance, exceeding sales growth guidance with a 7% increase to $9.6 billion for the year and achieving a core EBITDA of $1.7 billion, reflecting an 18.1% margin. The biosimilar segment saw significant growth, contributing 23% to total sales, up from 20% in 2022, with products like Omnitrope and the launch of Hyrimoz in the U.S. playing key roles. Despite a negative free cash flow of $234 million due to initial investments post-spin-off, Sandoz anticipates a robust cash flow increase by 2028. Looking forward to 2024, the company expects mid-single-digit net sales growth and core EBITDA margins to reach around 20%, driven by continued biosimilar momentum and operational efficiencies.Sandoz Group Ltd Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
62
Positive
Cash Flow
68
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.16B | 9.12B | 9.98B | 8.60B | 8.83B |
| Gross Profit | 5.28B | 4.31B | 4.56B | 4.05B | 4.20B |
| EBITDA | 2.29B | 667.55M | 857.00M | 1.53B | 1.68B |
| Net Income | 957.48M | 1.00M | 77.00M | 784.05M | 828.37M |
Balance Sheet | |||||
| Total Assets | 22.03B | 19.91B | 19.43B | 100.00K | 15.98B |
| Cash, Cash Equivalents and Short-Term Investments | 1.74B | 1.19B | 933.39M | 100.00K | 36.45M |
| Total Debt | 5.68B | 4.85B | 4.55B | 309.02M | 284.28M |
| Total Liabilities | 12.65B | 11.74B | 10.78B | 22.86K | 8.55B |
| Stockholders Equity | 9.38B | 8.16B | 7.28B | 77.14K | 7.43B |
Cash Flow | |||||
| Free Cash Flow | 810.00M | 60.00M | -242.64M | 760.23M | 855.75M |
| Operating Cash Flow | 1.59B | 656.00M | 325.31M | 1.17B | 1.24B |
| Investing Cash Flow | -980.00M | -740.00M | -551.77M | -410.68M | -631.76M |
| Financing Cash Flow | -197.00M | 242.00M | 1.24B | -734.45M | -600.67M |
Sandoz Group Ltd Technical Analysis
Positive
63.62
Price Trends
67.36
Positive
65.66
Positive
62.03
Positive
Market Momentum
0.30
Negative
65.47
Neutral
78.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SDZ, the sentiment is Positive. The current price of 63.62 is below the 20-day moving average (MA) of 65.86, below the 50-day MA of 67.36, and above the 200-day MA of 62.03, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 65.47 is Neutral, neither overbought nor oversold. The STOCH value of 78.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:SDZ.
Sandoz Group Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | CHF231.75B | 23.79 | ― | 2.92% | -5.88% | -11.57% | |
70 Outperform | CHF3.42B | 19.68 | 15.68% | 0.57% | 2.57% | 4.31% | |
66 Neutral | CHF38.31B | -365.06 | ― | 0.91% | -10.77% | -114.77% | |
62 Neutral | CHF28.93B | 38.23 | 10.09% | 1.26% | 0.80% | 28043.55% | |
62 Neutral | CHF27.67B | 41.53 | 3.69% | 0.50% | -3.08% | -33.39% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
CH:SDZ
Sandoz Group Ltd
72.78
26.31
56.60%
CH:NOVN
Novartis AG
125.98
32.80
35.19%
CH:LONN
Lonza Group Ltd
572.20
36.62
6.84%
CH:ALC
Alcon
57.34
-11.39
-16.57%
CH:SFZN
Siegfried Holding AG
79.65
-7.20
-8.29%
Sandoz Group Ltd Corporate Events
Sandoz H1 2026 profits surge as biosimilars drive growth and strategy
Aug 5, 2026
Sandoz reported first-half 2026 net sales of USD 5.8 billion, up 5% at constant currencies, driven by outstanding biosimilar growth of 20% and a return to generics growth in the second quarter. Biosimilars now account for a record 33% of net sales...
Sandoz seals major U.S. settlements in generic drug antitrust saga
Aug 3, 2026
Sandoz has moved to resolve legacy U.S. generic drug antitrust litigation by agreeing settlements with a consortium of 43 states and territories and a class of indirect reseller plaintiffs. The company will pay about USD 450 million to U.S. states...
Sandoz wins Brazilian approval for new semaglutide diabetes treatment
Jul 29, 2026
Sandoz has secured Brazilian marketing authorization from ANVISA for Owozy, a semaglutide treatment for type-2 diabetes developed by Adalvo and delivered via a multi-dose disposable pen. The product targets Brazil’s USD 1.8 billion GLP-1 mar...
Sandoz Reshapes Leadership to Seize Generics Growth Wave
Jul 15, 2026
Sandoz has announced a series of senior leadership changes designed to strengthen its manufacturing, MA and country-level operations. The reshuffle underscores the company’s intent to sharpen execution in its high-volume generics business an...
Sandoz to Join Swiss Market Index in Milestone for Post-Listing Growth
Jul 9, 2026
Sandoz has been selected for inclusion in the Swiss Market Index, Switzerland’s flagship blue-chip equity benchmark comprising the 20 largest and most liquid stocks on the SIX Swiss Exchange. The move comes less than three years after Sandoz...
Sandoz maps biosimilars ‘golden decade’ with capital markets day and Slovenia hub visit
Jun 22, 2026
Sandoz Group AG, a leading global provider of affordable generics and biosimilars, is deepening its push into what it terms a golden decade for biosimilars as it marks 20 years in the segment and 80 years in antibiotics manufacturing. Headquartere...
Sandoz opens flagship biosimilar R&D hub in Slovenia to anchor $1.1bn expansion
Jun 17, 2026
Sandoz has inaugurated a USD 99 million, fully digital biosimilar development centre in Ljubljana, Slovenia, marking 20 years since the launch of the world’s first biosimilar and significantly expanding its in-house RD capabilities. The 10,0...
Sandoz marks 80 years of European antibiotics and urges EU action to protect supply
May 28, 2026
Sandoz is marking 80 years of large-scale antibiotic manufacturing in Europe with a high-profile event at its Kundl, Austria site, highlighting its role as the last fully vertically integrated antibiotic producer on the continent. The company fram...
Sandoz wins EU approval for two insulin biosimilars, bolstering diabetes push
May 15, 2026
Sandoz has secured European Commission marketing authorisation for its biosimilar insulins Bysumlog (insulin lispro) and Dazparda (insulin aspart), both delivered in prefilled pens and developed with Gan Lee Pharmaceuticals. The products are appr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.